Tadalafil Use in Cardiovascular Disease

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Tadalafil is approved for erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH).
• Its cardiovascular benefits in ED and PAH have led to investigations into its potential use in heart failure (HF).

Purpose of the Study:

• To review the current evidence on tadalafil's efficacy and safety in patients with heart failure.
• To identify gaps in knowledge regarding tadalafil's role in HF prevention and treatment.

Main Methods:

• Review of preclinical animal studies demonstrating tadalafil's positive effects on cardiac function.
• Analysis of retrospective cohort studies and randomized controlled trials involving tadalafil in cardiovascular diseases.

Main Results:

• Animal models suggest tadalafil may improve left ventricular function and reduce adverse cardiac remodeling.
• A retrospective study indicated reduced HF incidence and mortality in patients with ED and coronary artery disease using tadalafil.
• A randomized trial showed no significant benefit in patients with comorbid PAH and HF with preserved ejection fraction.

Conclusions:

• Tadalafil's cardiovascular benefits are recognized, but its role in heart failure remains uncertain.
• Limited clinical trial data exists for tadalafil use in HF patients without comorbid PAH.
• Further research is essential to establish tadalafil's potential in preventing or treating heart failure.